Regulated information
December 18, 2017
Breda, the Netherlands / Ghent, Belgium -
argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology
company developing a deep pipeline of differentiated antibody-based
therapies for the treatment of severe autoimmune diseases and
cancer, announced today the closing of its public offering in the
United States of 5,106,000 American Depositary Shares (ADSs), at a
price of $52.00 per ADS, for gross proceeds of approximately $266
million. This includes the full exercise of the underwriters'
option to purchase additional ADSs.
Each of the ADSs offered represents the right to
receive one ordinary share, nominal value of €0.10 per share.
argenx's ADSs are currently listed on the Nasdaq Global Select
Market under the symbol "ARGX," and argenx's ordinary shares are
currently listed on Euronext Brussels.
Cowen and Piper Jaffray & Co. acted as joint
bookrunning managers for the Offering, and JMP Securities and
Wedbush PacGrow acted as co-managers. Kempen & Co was argenx's
advisor in connection with the Offering.
A registration statement relating to these
securities was declared effective by the U.S. Securities and
Exchange Commission (SEC) on December 13, 2017. This registration
statement can be accessed through the SEC's website at
www.sec.gov.
Copies of the final prospectus for this Offering
may be obtained for free from Cowen and Company, LLC, c/o
Broadridge Financial Services, 1155 Long Island Avenue, Edgewood,
NY 11717, Attn: Prospectus Department, by telephone at (631)
274-2806 or by fax at (631) 254-7140 or from Piper Jaffray &
Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, MN 55403, or by telephone at (800)747-3924, or by
email at prospectus@pjc.com.
In addition, argenx announced today the listing
of and the commencement of dealings in its 5,106,000 new ordinary
shares underlying the ADSs (the New Ordinary Shares) on the
regulated market of Euronext Brussels, effective today, following
Euronext Brussels' approval of argenx's request for the admission
to listing and trading of the New Ordinary Shares on the regulated
market of Euronext Brussels.
This press release is for information purposes
only and does not constitute, and should not be construed as, an
offer to sell or the solicitation of an offer to buy or subscribe
to any securities, nor shall there be any sale of securities in any
jurisdiction in which such offer, solicitation or sale is not
permitted or to any person or entity to whom it is unlawful to make
such offer, solicitation or sale. Reference is also made to the
restrictions set out in "Important information" below. This press
release is not for publication or distribution, directly or
indirectly, in or into any state or jurisdiction into which doing
so would be unlawful or where a prior registration or approval is
required for such purpose.
About argenxargenx is a clinical-stage
biotechnology company developing a deep pipeline of differentiated
antibody-based therapies for the treatment of severe autoimmune
diseases and cancer. We are focused on developing product
candidates with the potential to be either first-in-class against
novel targets or best-in-class against known, but complex, targets
in order to treat diseases with a significant unmet medical need.
Our ability to execute on this focus is enabled by our suite of
differentiated technologies. Our SIMPLE Antibody(TM) Platform,
based on the powerful llama immune system, allows us to exploit
novel and complex targets, and our three antibody engineering
technologies are designed to enable us to expand the therapeutic
index of our product candidates.
www.argenx.com
For further information, please
contact:
Joke Comijn, Corporate Communications Manager
+32 (0)477 77 29 44+32 (0)9 310 34 19info@arGEN-X.com
Beth DelGiacco (US IR)Stern Investor Relations+1
212 362 1200beth@sternir.com
Forward-looking StatementsThe contents of
this announcement include statements that are, or may be deemed to
be, "forward-looking statements." These forward-looking statements
can be identified by the use of forward-looking terminology,
including the terms "believes," "estimates," "anticipates,"
"expects," "intends," "may," "will," or "should." By their nature,
forward-looking statements involve risks and uncertainties and
readers are cautioned that any such forward-looking statements are
not guarantees of future performance. argenx's actual results may
differ materially from those predicted by the forward-looking
statements as a result of various important factors, including
argenx's expectations regarding its the inherent uncertainties
associated with competitive developments, preclinical and clinical
trial and product development activities and regulatory approval
requirements; argenx's reliance on collaborations with third
parties; estimating the commercial potential of argenx's product
candidates; argenx's ability to obtain and maintain protection of
intellectual property for its technologies and drugs; argenx's
limited operating history; and argenx's ability to obtain
additional funding for operations and to complete the development
and commercialization of its product candidates. A further list and
description of these risks, uncertainties and other risks can be
found in argenx's SEC filings and reports, including in the final
prospectus related to argenx's U.S. public offering filed with the
SEC pursuant to Rule 424(b) of the Securities Act of 1933, as
amended, as well as subsequent filings and reports filed by argenx
with the SEC. Given these uncertainties, the reader is advised not
to place any undue reliance on such forward-looking statements.
These forward-looking statements speak only as of the date of
publication of this document. argenx undertakes no obligation to
publicly update or revise the information in this press release,
including any forward-looking statements, except as may be required
by law.
Important informationNo public offering
will be made and no one has taken any action that would, or is
intended to, permit a public offering in any country or
jurisdiction, other than the United States, where any such action
is required, including in the European Economic Area. In the
European Economic Area, the transaction to which this press release
relates will only be available to, and will be engaged in only
with, qualified investors within the meaning of Directive
2003/71/EC (together with any applicable implementing measures in
the relevant member state of the European Economic Area and as
amended, including by Directive 2010/73/EU, to the extent
implemented in the relevant member state).
In addition, in the United Kingdom, the
transaction to which this press release relates will only be
available to, and will be engaged in only with, investment
professionals falling within Article 19(5) of the Financial
Services and Markets Act (Financial Promotion) Order 2005, as
amended (the Order), persons falling within Article 49(2)(a) to (d)
of the Order, and other persons to whom this announcement may
lawfully be communicated (all such persons together being referred
to as "relevant persons"). The securities referred to herein are
only available to, and any invitation, offer or agreement to
subscribe, purchase or otherwise acquire such securities will be
engaged in only with relevant persons. Any person who is not a
relevant person should not act or rely on this communication or any
of its contents.
Argen X (EU:ARGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Argen X (EU:ARGX)
Historical Stock Chart
From Sep 2023 to Sep 2024